Show simple item record

dc.contributor.authorFindling, Robert L.
dc.contributor.authorJohnson, Jacqueline L.
dc.contributor.authorMcClellan, Jon
dc.contributor.authorFrazier, Jean A.
dc.contributor.authorVitiello, Benedetto
dc.contributor.authorHamer, Robert M.
dc.contributor.authorLieberman, Jeffrey A.
dc.contributor.authorRitz, Louise
dc.contributor.authorMcNamara, Nora K.
dc.contributor.authorLingler, Jacqui
dc.contributor.authorHlastala, Stefanie A.
dc.contributor.authorPierson, Leslie
dc.contributor.authorPuglia, Madeline
dc.contributor.authorMaloney, Ann E.
dc.contributor.authorKaufman, Emily Michael
dc.contributor.authorNoyes, Nancy
dc.contributor.authorSikich, Linmarie
dc.date2022-08-11T08:10:27.000
dc.date.accessioned2022-08-23T17:09:46Z
dc.date.available2022-08-23T17:09:46Z
dc.date.issued2010-05-25
dc.date.submitted2011-02-10
dc.identifier.citationJ Am Acad Child Adolesc Psychiatry. 2010 Jun;49(6):583-94; quiz 632. Epub 2010 May 1. <a href="http://dx.doi.org/10.1016/j.jaac.2010.03.013">Link to article on publisher's site</a>
dc.identifier.issn0890-8567 (Linking)
dc.identifier.doi10.1016/j.jaac.2010.03.013
dc.identifier.pmid20494268
dc.identifier.urihttp://hdl.handle.net/20.500.14038/45897
dc.description.abstractOBJECTIVE: To examine the long-term safety and efficacy of three antipsychotics in early-onset schizophrenia spectrum disorders. METHOD: Patients (8 to 19 years old) who had improved during an 8-week, randomized, double-blind acute trial of olanzapine, risperidone, or molindone (plus benztropine) were eligible to continue on the same medication for up to 44 additional weeks under double-blind conditions. Adjunctive medications were allowed according to defined algorithms. Standardized symptom, safety, and functional assessments were conducted every 4 weeks. RESULTS: Of the 116 youths randomized in the acute trial, 54 entered maintenance treatment (molindone, n = 20; olanzapine, n = 13; risperidone, n = 21). Fourteen (26%) completed 44 weeks of treatment. Adverse effects (n = 15), inadequate efficacy (n = 14), or study nonadherence (n = 8) were the most common reasons for discontinuation. The three treatment arms did not significantly differ in symptom decrease or time to discontinuation. Akathisia was more common with molindone and elevated prolactin concentrations more common with risperidone. Although weight gain and metabolic adverse events had occurred more often with olanzapine and risperidone during the acute trial, no significant between-drug differences emerged in most of these parameters during maintenance treatment. CONCLUSIONS: Only 12% of youths with early-onset schizophrenia spectrum disorders continued on their originally randomized treatment at 52 weeks. No agent demonstrated superior efficacy, and all were associated with side effects, including weight gain. Improved treatments are needed for early-onset schizophrenia spectrum disorders. Clinical trial registry information-Treatment of Schizophrenia and Related Disorders in Children and Adolescents; URL: http://www.clinicaltrials.gov, unique identifier: NCT00053703. Elsevier Inc. All rights reserved.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=20494268&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/j.jaac.2010.03.013
dc.subjectAdolescent
dc.subjectAkathisia, Drug-Induced
dc.subjectBenzodiazepines
dc.subjectChild
dc.subjectDouble-Blind Method
dc.subjectFemale
dc.subjectHumans
dc.subjectLong-Term Care
dc.subjectMale
dc.subjectMolindone
dc.subjectProlactin
dc.subjectPsychiatric Status Rating Scales
dc.subjectPsychotic Disorders
dc.subjectPsychotropic Drugs
dc.subjectRisk Factors
dc.subjectRisperidone
dc.subjectSchizophrenia
dc.subject*Schizophrenic Psychology
dc.subjectWeight Gain
dc.subjectYoung Adult
dc.subjectPsychiatry
dc.titleDouble-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study
dc.typeJournal Article
dc.source.journaltitleJournal of the American Academy of Child and Adolescent Psychiatry
dc.source.volume49
dc.source.issue6
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/psych_pp/423
dc.identifier.contextkey1775363
html.description.abstract<p>OBJECTIVE: To examine the long-term safety and efficacy of three antipsychotics in early-onset schizophrenia spectrum disorders.</p> <p>METHOD: Patients (8 to 19 years old) who had improved during an 8-week, randomized, double-blind acute trial of olanzapine, risperidone, or molindone (plus benztropine) were eligible to continue on the same medication for up to 44 additional weeks under double-blind conditions. Adjunctive medications were allowed according to defined algorithms. Standardized symptom, safety, and functional assessments were conducted every 4 weeks.</p> <p>RESULTS: Of the 116 youths randomized in the acute trial, 54 entered maintenance treatment (molindone, n = 20; olanzapine, n = 13; risperidone, n = 21). Fourteen (26%) completed 44 weeks of treatment. Adverse effects (n = 15), inadequate efficacy (n = 14), or study nonadherence (n = 8) were the most common reasons for discontinuation. The three treatment arms did not significantly differ in symptom decrease or time to discontinuation. Akathisia was more common with molindone and elevated prolactin concentrations more common with risperidone. Although weight gain and metabolic adverse events had occurred more often with olanzapine and risperidone during the acute trial, no significant between-drug differences emerged in most of these parameters during maintenance treatment.</p> <p>CONCLUSIONS: Only 12% of youths with early-onset schizophrenia spectrum disorders continued on their originally randomized treatment at 52 weeks. No agent demonstrated superior efficacy, and all were associated with side effects, including weight gain. Improved treatments are needed for early-onset schizophrenia spectrum disorders.</p> <p>Clinical trial registry information-Treatment of Schizophrenia and Related Disorders in Children and Adolescents; URL: http://www.clinicaltrials.gov, unique identifier: NCT00053703. Elsevier Inc. All rights reserved.</p>
dc.identifier.submissionpathpsych_pp/423
dc.contributor.departmentDepartment of Psychiatry
dc.source.pages583-94; quiz 632


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record